Revance Therapeutics Inc (RVNC)

[DewDiligence]

Hyperhidrosis is a tiny portion of the therapeutics market for botulinum toxin, so I don't think RVNC can justify the cost of running clinical trials in that indication. Daxxify will get some off-label sales for hyperhidrosis even without clinical data, as dewophile just said.

RVNC tested its (now discontinued) topical toxin formulation in hyperhidrosis, but the trial was a failure (#msg-119391369).